Cárdenas-Mondragón Guadalupe, Ulloa-Aguirre Alfredo, Isordia-Salas Irma, Goffin Vincent, Leaños-Miranda Alfredo
Research Unit in Reproductive Medicine, Hospital de Ginecología y Obstetricia Luis Castelazo Ayala, Instituto Mexicano del Seguro Social, México DF, Mexico.
J Rheumatol. 2007 Jul;34(7):1514-21. Epub 2007 May 15.
To assess the bioactivity of circulating prolactin (PRL) in serum samples from patients with systemic lupus erythematosus (SLE) using 2 novel homologous in vitro bioassays, and to correlate PRL bioactivity with lupus activity.
Serum samples from 98 SLE patients with and without disease activity were tested for immunoreactive and bioactive concentrations of PRL.
Patients with active disease exhibited higher bioactive serum PRL levels in homologous bioassays (p <or= 0.013). In contrast, bioactivity in Nb2 cells was similar between patients with and without activity. The bioactive/immunoreactive PRL ratio (BA/IA) in homologous bioassays was significantly higher in patients with both clinical manifestations and serological indicators of lupus disease activity. SLE patients with idiopathic hyperprolactinemia (HPRL) and macroprolactinemia (MPRL) had low SLEDAI scores, and the BA/IA ratio in homologous bioassays was significantly lower compared to those with idiopathic HPRL and no MPRL. There was a negative but significant correlation between MPRL and BA/IA in homologous bioassays (p < 0.001), but not when the heterologous bioassay was employed.
Elevated serum bioactive PRL levels revealed by homologous bioassays were associated with disease activity, as well as with specific organ involvement. Big big PRL or macroprolactin is a PRL variant with reduced bioactivity towards its homologous receptor, and this altered bioactivity may contribute to the lower disease activity and absence of symptoms related to HPRL in SLE patients. These novel data must be considered in future studies to establish a relationship between PRL and disease activity in SLE.
使用两种新型同源体外生物测定法评估系统性红斑狼疮（SLE）患者血清样本中循环催乳素（PRL）的生物活性，并将PRL生物活性与狼疮活动度相关联。
对98例有或无疾病活动的SLE患者的血清样本进行PRL免疫反应性和生物活性浓度检测。
在同源生物测定中，疾病活动期患者的血清PRL生物活性水平较高（p≤0.013）。相比之下，有活动和无活动的患者在Nb2细胞中的生物活性相似。在具有狼疮疾病活动的临床表现和血清学指标的患者中，同源生物测定中的生物活性/免疫反应性PRL比值（BA/IA）显著更高。患有特发性高催乳素血症（HPRL）和大分子催乳素血症（MPRL）的SLE患者SLEDAI评分较低，与患有特发性HPRL且无MPRL的患者相比，同源生物测定中的BA/IA比值显著更低。在同源生物测定中，MPRL与BA/IA之间存在负相关但显著相关（p<0.001），但采用异源生物测定时则无此相关性。
同源生物测定显示血清生物活性PRL水平升高与疾病活动度以及特定器官受累有关。大分子PRL或大分子催乳素是一种对其同源受体生物活性降低的PRL变体，这种改变的生物活性可能导致SLE患者疾病活动度较低以及缺乏与HPRL相关的症状。在未来研究中建立PRL与SLE疾病活动度之间的关系时，必须考虑这些新数据。
